M. Harada

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo et al. · Annals of Oncology · 2012 · 554 citations

Medicine, Oncology, Pharmacology +15

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Hajime Asahina, K Yamazaki, Ichiro Kinoshita et al. · British Journal of Cancer · 2006 · 278 citations · Full text

Medicine, Oncology, Pharmacology +14

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902

Shunichi Sugawara, Satoshi Oizumi, Koichi Minato et al. · Annals of Oncology · 2015 · 110 citations · Full text

Medicine, Oncology, Pharmacology +12

2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

C. Zhou, Meghna Das Thakur, Manoj Srivastava et al. · Annals of Oncology · 2021 · 66 citations

Medicine, Clinical Sciences, Oncology +15

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

Kengo Takeuchi, Yosuke Togashi, Yuki Kamihara et al. · Annals of Oncology · 2015 · 58 citations · Full text

Medicine, Molecular Medicine, Oncology +15